http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Press+Releases/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html <p align="justify" style="padding-left:0pt;">CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs.</p> <p align="justify">The Company’s current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Corporate+Update+and+Announces+Appointment+of+Mika+Grasso+as+Co-CEO/26644058.html Mon, 15 Jun 2026 07:00:00 -0400 A.06822034 A.30466919 A.36078215 ANU O.02555813 O.20026344 O.28729799 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Election+to+Voluntary+Delist+from+the+TSX+Venture+Exchange/26641825.html <p align="justify">CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release.</p> <p align="justify">This decision was taken following a comprehensive evaluation, the Company determined that maintaining a http://www.streetinsider.com/Press+Releases/XORTX+Announces+Election+to+Voluntary+Delist+from+the+TSX+Venture+Exchange/26641825.html Fri, 12 Jun 2026 17:00:00 -0400 A.36078215 ANU O.02555813 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Election+to+Voluntary+Delist+from+the+TSX+Venture+Exchange/26641825.html <p align="justify">CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release.</p> <p align="justify">This decision was taken following a comprehensive evaluation, the Company determined that maintaining a http://www.streetinsider.com/Press+Releases/XORTX+Announces+Election+to+Voluntary+Delist+from+the+TSX+Venture+Exchange/26641825.html Fri, 12 Jun 2026 17:00:00 -0400 A.36078215 ANU O.02555813 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Election+to+Voluntary+Delist+from+the+TSX+Venture+Exchange/26641825.html <p align="justify">CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release.</p> <p align="justify">This decision was taken following a comprehensive evaluation, the Company determined that maintaining a http://www.streetinsider.com/Press+Releases/XORTX+Announces+Election+to+Voluntary+Delist+from+the+TSX+Venture+Exchange/26641825.html Fri, 12 Jun 2026 17:00:00 -0400 A.36078215 ANU O.02555813 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Election+to+Voluntary+Delist+from+the+TSX+Venture+Exchange/26641825.html <p align="justify">CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release.</p> <p align="justify">This decision was taken following a comprehensive evaluation, the Company determined that maintaining a http://www.streetinsider.com/Press+Releases/XORTX+Announces+Election+to+Voluntary+Delist+from+the+TSX+Venture+Exchange/26641825.html Fri, 12 Jun 2026 17:00:00 -0400 A.36078215 ANU O.02555813 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Election+to+Voluntary+Delist+from+the+TSX+Venture+Exchange/26641825.html <p align="justify">CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release.</p> <p align="justify">This decision was taken following a comprehensive evaluation, the Company determined that maintaining a http://www.streetinsider.com/Press+Releases/XORTX+Announces+Election+to+Voluntary+Delist+from+the+TSX+Venture+Exchange/26641825.html Fri, 12 Jun 2026 17:00:00 -0400 A.36078215 ANU O.02555813 O.28734418 XRTX XRTX